Levodropropizinum
This medicine should always be taken exactly as described in this package leaflet for the patient or as directed by the doctor or pharmacist.
Adrimax contains the active substance levodropropizine, which has antitussive and bronchodilatory effects.
Adrimax is indicated for the symptomatic treatment of non-productive (dry) cough.
Many data indicate that this medicine effectively inhibits cough of various origins, such as cough in lung cancer, cough associated with upper and lower respiratory tract infections, or whooping cough.
If there is no improvement after 7 days or if you feel worse, consult a doctor.
Before starting treatment with Adrimax, discuss it with your doctor or pharmacist.
Adrimax is a medicine used for the symptomatic treatment of non-productive (dry) cough and should only be used while waiting for a diagnosis of the cause of the cough and/or the effect of treatment of the underlying disease.
Particular caution should be exercised when using levodropropizine in elderly patients, as there is evidence of changes in sensitivity to many drugs in this group of patients.
Caution is recommended when using the medicine in patients with severe renal impairment (creatinine clearance <35 ml min.).< p>
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
In human studies, no changes in EEG recording were found during administration of levodropropizine in combination with benzodiazepines.
In sensitive individuals, caution should be exercised when taking sedatives.
Due to the lack of information on the effect of meals on the absorption of the medicine, it is recommended to take it between meals.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before taking this medicine.
The medicine is contraindicated in pregnant or breastfeeding women, as well as in women planning to become pregnant.
No studies have been conducted to assess the ability to drive and/or operate machinery.
However, since the medicine may rarely cause drowsiness (see also section 4 "Possible side effects"), caution should be exercised in patients who intend to drive vehicles or operate mechanical equipment and inform them of this possibility.
If you have previously been diagnosed with intolerance to some sugars, consult your doctor before taking the medicine.
The medicine contains 3 g of sucrose in 5 ml of syrup. This should be taken into account in patients with diabetes.
The medicine contains less than 1 mmol (23 mg) of sodium per 10 ml of syrup, which means the medicine is considered "sodium-free".
The medicine contains small amounts of ethanol (alcohol), less than 100 mg per maximum daily dose.
This medicine should always be taken exactly as described in this package leaflet for the patient or as directed by the doctor or pharmacist. If in doubt, consult a doctor or pharmacist. Do not take Adrimax for more than 7 days without consulting a doctor.
Body weight 10-20 kg: the recommended dose is 3 ml of syrup 3 times a day;
Body weight 20-30 kg: the recommended dose is 5 ml of syrup 3 times a day.
The recommended dose is 10 ml of syrup up to 3 times a day.
Adrimax should be taken orally, 3 times a day, at intervals of at least 6 hours. The bottle of syrup comes with a measuring cup that allows you to measure 3 ml, 5 ml, and 10 ml.
The bottle is equipped with an additional safety feature, a child-resistant closure. To open the bottle, press the cap and turn it in the direction indicated by the arrow.
Treatment should be continued until the cough disappears or as directed by the doctor.
In any case, if the cough does not disappear after 7 days of treatment, discontinue use and consult a doctor. Remember that cough is a symptom of a disease. In this situation, the doctor should make a proper diagnosis and then initiate appropriate treatment.
If you have taken more than the recommended dose of the medicine, tell your doctor or pharmacist immediately. In case of overdose with clinical symptoms, the doctor will immediately initiate symptomatic treatment and, if necessary, apply standard emergency procedures (gastric lavage, activated charcoal, parenteral fluid administration, etc.).
If you forget to take a dose of Adrimax, take the next dose at the usual time. Do not take a double dose to make up for a missed dose.
If you have any further doubts about taking this medicine, consult a doctor or pharmacist.
Like all medicines, Adrimax can cause side effects, although not everybody gets them.
During treatment with Adrimax, side effects are very rare. In most cases, they are not serious and symptoms disappear after discontinuation of treatment, sometimes only requiring specific pharmacological treatment.
Very rare(occurring in less than 1 in 10,000 patients):
The following side effects have also been reported:
Taking Adrimax as directed in the package leaflet for the patient reduces the risk of side effects.
If you experience any side effects, including those not listed in the package leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Pharmacovigilance of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medicine.
Keep the medicine out of sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
The shelf life after first opening the bottle is 6 months.
Store in the original orange bottle to protect from light.
Do not store in the refrigerator or freeze.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Adrimax is a syrup.
The packaging consists of an orange glass type III bottle with a PP/PE or PP child-resistant closure and a PE seal, and a PP measuring cup scaled at 2 ml, 2.5 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 7.5 ml, 8 ml, 9 ml, 10 ml, 11 ml, 12 ml, 12.5 ml, and 15 ml in a cardboard box.
Available packages:
Pharmaceutical Works POLPHARMA S.A.
ul. Pelplińska 19
83-200 Starogard Gdański
phone: +48 22 364 61 01
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park, Paola, PLA3000
Malta
Malta
Levodropropizine ELC
Date of last revision of the package leaflet:May 2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.